The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Study Type
OBSERVATIONAL
Enrollment
1,000
KUCC - Indian Creek
Overland Park, Kansas, United States
ACTIVE_NOT_RECRUITINGKUCC - Overland Park
Overland Park, Kansas, United States
ACTIVE_NOT_RECRUITINGKUCC - Briarcliff
Westwood, Kansas, United States
Overall survival rate
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
Time frame: From diagnosis to 5 years after diagnosis
Pathologic complete response rate
Percentage of patients with stage I-III HER2-positive breast cancer who received neoadjuvant systemic therapy and experienced pathologic complete response.
Time frame: From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
KUCC - Olathe
Westwood, Kansas, United States
ACTIVE_NOT_RECRUITINGThe University of Kansas Cancer Center
Westwood, Kansas, United States
RECRUITINGKUCC - Lee's Summit
Lee's Summit, Missouri, United States
ACTIVE_NOT_RECRUITING